Skip to Content
Merck
  • Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Biochimica et biophysica acta. Molecular and cell biology of lipids (2020-04-15)
Shobini Jayaraman, Olivia R Chavez, Antonio Pérez, Inka Miñambres, Jose Luis Sánchez-Quesada, Olga Gursky
ABSTRACT

Low-density lipoprotein (LDL) binding to arterial proteoglycans initiates LDL retention and modification in the arterial wall, triggering atherosclerosis. The details of this binding, its effectors, and its ramifications are incompletely understood. We combined heparin affinity chromatography with biochemical, spectroscopic and electron microscopic techniques to show that brief binding to heparin initiates irreversible pro-atherogenic remodeling of human LDL. This involved decreased structural stability of LDL and increased susceptibility to hydrolysis, oxidation and fusion. Furthermore, phospholipid hydrolysis, mild oxidation and/or glycation of LDL in vitro increase the proteolytic susceptibility of apoB and its heparin binding affinity, perhaps by unmasking additional heparin-binding sites. For LDL from hyperglycemic type-2 diabetic patients, heparin binding was particularly destabilizing and caused apoB fragmentation and LDL fusion. However, for similar patients whose glycemic control was restored upon therapy, LDL-heparin binding affinity was rectified and LDL structural stability was partially restored. These results complement previous studies of LDL binding to arterial proteoglycans and suggest that such interactions may produce a particularly pro-atherogenic subclass of electronegative LDL. In summary, binding to heparin alters apoB conformation, perhaps by partially peeling it off the lipid, and triggers pro-atherogenic LDL modifications including hydrolysis, oxidation, and destabilization. Furthermore, phospholipid lipolysis, mild oxidation and glycation of LDL in vitro strengthen its binding to heparin, which helps explain stronger binding observed in hyperglycemic LDL. Combined effects of hyperglycemia and heparin binding are especially deleterious but are largely rectified upon diabetes therapy. These findings help establish a mechanistic link between diabetes and atherosclerosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Matrix Metalloproteinase-12, Catalytic Domain human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), buffered aqueous glycerol solution
Sigma-Aldrich
Plasmin from human plasma, lyophilized powder, ≥2.0 units/mg protein
Sigma-Aldrich
Trypsin from bovine pancreas, TPCK Treated, essentially salt-free, lyophilized powder, ≥10,000 BAEE units/mg protein
Sigma-Aldrich
Lipase from porcine pancreas, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
Phospholipase C from Bacillus cereus, ≥200 units/mg protein
Sigma-Aldrich
Apolipoprotein E, human
Sigma-Aldrich
Sodium oleate, ≥99%
Sigma-Aldrich
Sphingomyelinase from Bacillus cereus, buffered aqueous glycerol solution, ≥100 units/mg protein (Lowry)
Sigma-Aldrich
Heparin sodium salt from porcine intestinal mucosa, ≥180 USP units/mg
Sigma-Aldrich
Methylglyoxal solution, ~40% in H2O
Sigma-Aldrich
Heparin sodium salt from porcine intestinal mucosa, Grade I-A, ≥180 USP units/mg
Sigma-Aldrich
Phenylmethanesulfonyl fluoride solution, ~0.1 M in ethanol (T)
Sigma-Aldrich
Apolipoprotein C-III, human
Sigma-Aldrich
Anti-Apolipoprotein E Antibody, serum, Chemicon®
Sigma-Aldrich
Myeloperoxidase, Human Polymorphonuclear Leukocytes, A lysosomal enzyme that catalyzes oxidations by hydrogen peroxide, including MPO-chloride-mediated killing of microbes and tumor cells, inactivation of chemotactic factors, and cross-linking of proteins.